Real-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with Mutated Acute Myeloid Leukemia: A Multicenter Study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
12 patients).
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Treatment discontinuation due to intolerance or toxicity was low (3.5%).
Real-world data on the therapeutic use of FLT3 inhibitors in Turkey remain limited.
APA
Seçilmiş S, Kabukçu Hacıoğlu S, et al. (2026). Real-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with Mutated Acute Myeloid Leukemia: A Multicenter Study.. Journal of clinical medicine, 15(2). https://doi.org/10.3390/jcm15020854
MLA
Seçilmiş S, et al.. "Real-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with Mutated Acute Myeloid Leukemia: A Multicenter Study.." Journal of clinical medicine, vol. 15, no. 2, 2026.
PMID
41598791 ↗
Abstract 한글 요약
Real-world data on the therapeutic use of FLT3 inhibitors in Turkey remain limited. Therefore, we retrospectively evaluated outcomes from 13 academic centers nationwide, focusing on the multikinase inhibitor midostaurin in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). We collected comprehensive information regarding treatment efficacy, safety, and tolerability. The overall response rate to intensive chemotherapy (3 + 7) plus midostaurin was 87.7%, with a complete remission rate of 84.2%, consistent with previously reported clinical trial results. Treatment discontinuation due to intolerance or toxicity was low (3.5%). One patient discontinued therapy because of septic shock during induction, and another due to a drug-drug interaction during consolidation. Median overall survival was 21.4 months. Allogeneic stem cell transplantation was performed in first remission in 52.6% of patients. Five patients (8.8%) were refractory to induction therapy, and relapse occurred in 21.1% (12 patients). These findings support the effectiveness and acceptable tolerability of midostaurin in routine clinical practice for FLT3-mutated AML.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial.
- Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.
- Immunophenotypic Heterogeneity and Clonal Sweep in Acute Myeloid Leukemia Revealed by Flow Cytometry: A Case Series Study.
- Editorial: Exploiting biomarkers for targeted therapies in acute myeloid leukemia.
- Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand.
- Leukemic appendix with clinical presentation that mimics acute appendicitis.